{"disease":{"id":"amebiasis","name":"amebiasis"},"drugs":{"marketed":[{"drug_id":"tinidazole","indication_name":"Amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tindamax","generic_name":"TINIDAZOLE","company_name":"Mission Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Tindamax works by damaging the DNA of susceptible microorganisms, ultimately leading to their death."},{"drug_id":"doxycycline","indication_name":"Acute intestinal amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Acute amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"carbarsone","indication_name":"Acute amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aminarson","generic_name":"carbarsone","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"carbarsone","quality_score":null,"revenue":null,"mechanism":"Aminarson works by inhibiting the growth of the parasite Entamoeba histolytica, ultimately leading to its death."},{"drug_id":"glycobiarsol","indication_name":"Acute amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Milibis","generic_name":"GLYCOBIARSOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"glycobiarsol","quality_score":null,"revenue":null,"mechanism":"Milibis works by inhibiting the growth and replication of the amoeba Entamoeba histolytica."},{"drug_id":"tinidazole","indication_name":"Acute amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tindamax","generic_name":"TINIDAZOLE","company_name":"Mission Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Tindamax works by damaging the DNA of susceptible microorganisms, ultimately leading to their death."},{"drug_id":"paromomycin","indication_name":"Acute amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ameparomo","generic_name":"PAROMOMYCIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Antiprotozoal","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"paromomycin","indication_name":"Chronic intestinal amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ameparomo","generic_name":"PAROMOMYCIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Antiprotozoal","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metronidazol","indication_name":"Acute amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00001162","title":"Parasitic Infections of the Gastrointestinal Tract","phase":"","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02680665","title":"Ameparomo Capsules 250 mg Drug Use Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Pfizer","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}